ALFA Finder| Metric | H1 FY27 | H2 FY26 | H1 FY26 |
|---|---|---|---|
| Revenue from operations | 87.0 | 44.8 | 30.5 |
| Other income | 0.2 | 0.7 | 0.1 |
| Total income | 87.2 | 45.5 | 30.6 |
| Profit before exceptional items & tax | 8.9 | 8.1 | 4.9 |
| Profit before tax | 8.9 | 8.1 | 4.9 |
| Net profit | 8.9 | 8.2 | 4.9 |
| Operating margin | 10.2% | 17.8% | 16.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +81.60% |
|---|---|
| Net profit, quarter on quarter | +8.50% |
| Revenue, year on year | +185.20% |
| Operating profit, year on year | +81.20% |
| Operating profit, quarter on quarter | +17.60% |
BSE results filing, BSE: 544738. Figures extracted from the filing.
Speciality Medicines Ltd: key numbers
- Share price
- ₹169.40
- Market cap
- ₹148.8 Cr
- Revenue (annual)
- ₹75.29 Cr
- Net profit (annual)
- ₹13.03 Cr
- P/E (TTM)
- 11.4×Sector 43.7×
- Promoter holding
- 43.43%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Speciality Medicines Ltd
All →Speciality Medicines Board Meeting Date
Speciality Medicines Limited has scheduled a board meeting on November 12, 2026. The board will consider and approve unaudited standalone financial results for the half-year ended September 30, 2026.
Speciality Medicines Other Announcement
Speciality Medicines Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31.
Speciality Medicines Annual General Meeting
Speciality Medicines Limited conducted its 5th Annual General Meeting on September 28, 2026. Shareholders considered the adoption of FY26 audited financial statements and the re-appointment of Director Sumit Goyani.
Speciality Medicines Annual Report
Speciality Medicines Limited has submitted its Annual Report for the financial year 2025-26 to the exchange, complying with regulatory filing requirements.
Speciality Medicines Annual General Meeting
Speciality Medicines Limited scheduled its 5th Annual General Meeting for September 28, 2026. The board also approved the draft Directors' Report for FY 2025-26.
Speciality Medicines Regulatory Approval
Speciality Medicines Limited received regulatory approval in Ethiopia for two additional pharmaceutical formulations, Olanzapine and Diazepam tablets. The company now has 12 registered products in Ethiopia.